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ABSTRACT
Current epidemiological trends of infective endocarditis (IE) in Greece were investigated via a
prospective cohort study of all cases of IE that fulfilled the Duke criteria during 2000–2004 in 14 tertiary
and six general hospitals in the metropolitan area of Athens. Demographics, clinical data and outcome
were compared for nosocomial IE (NIE) and community-acquired IE (CIE). NIE accounted for 42
(21.5%) and CIE for 153 (78.5%) of 195 cases. Intravenous drug use was associated exclusively with CIE,
while co-morbidities (cardiovascular disease, diabetes mellitus, chronic renal failure requiring
haemodialysis and malignancies) were more frequent in the NIE group (p <0.05). Prosthetic valve
endocarditis (PVE) predominated in the NIE group (p 0.006), and >50% of NIE cases had a history of
vascular intervention. Coagulase-negative staphylococci and enterococci were more frequent in cases of
NIE than in cases of CIE (26.2% vs. 5.2%, p <0.01, and 30.9% vs. 16.3%, p 0.05, respectively).
Enterococci accounted for 19.5% of total IE cases and were the leading cause of NIE. Staphylococcus
aureus IE was hospital-acquired in only 11.9% of cases. In-hospital mortality was higher for NIE than for
CIE (39.5% vs. 18.6%, p 0.02). Cardiac failure (New York Heart Association grade III–IV; OR 13.3,
95% CI 4.9–36.1, p <0.001) and prosthetic valve endocarditis (OR 3.7, 95% CI 1.3–10.6, p 0.01) were the
most important predictors of mortality.
Keywords Community-acquired, Enterococcus spp., Greece, infective endocarditis, nosocomial, Staphylococcus
aureus
Original Submission: 24 October 2006; Revised Submission: 8 February 2007; Accepted: 4 March 2007
Clin Microbiol Infect 2007; 13: 763–769
INTRODUCTION
Infective endocarditis (IE) is a disease associated
with significant mortality, despite appropriate
antimicrobial therapy and cardiac surgery inter-
vention [1]. Categories of IE often mentioned
include native valve endocarditis (NVE), pros-
thetic valve endocarditis (PVE), endocarditis in
intravenous drug users and in haemodialysis
patients, and nosocomial infective endocarditis
(NIE). NIE complicates nosocomial bacteraemia,
especially in elderly ⁄ seriously-ill patients, or in
patients with prosthetic valves and ⁄or intravascular
devices [2,3]. The changing epidemiological
profile of community-acquired infective endo-
carditis (CIE) indicates a need for continuous
epidemiological surveillance of this disease [4].
International, as well as local, endocarditis
surveillance networks have been established for
this purpose [1,4–9]. A prospective, observational
epidemiological survey using a database registry
that included 20 general hospitals in the metro-
politan area of Athens, Greece, was launched in
2000. The aim of the present study was to sum-
marise the current trends of NIE and CIE in the
Greek population, focusing on epidemiological
issues and risk-factors for an adverse outcome.
PATIENTS AND METHODS
A standardised electronic database was created in order to
record every definite or possible case of IE, defined according
to the modified Duke criteria [10]. Fourteen tertiary and six
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community-care general hospitals in the metropolitan area of
Athens contributed to the database. All cases of IE recorded
between January 2000 and May 2004 were included in the
study, which was approved by the institutional review boards
and ethical committees of all the participating hospitals.
Information concerning patient demographics, predispo-
sing IE factors (i.e., previously known valve disease, history
of IE, prosthetic valve and injection drug use), co-morbidi-
ties (i.e., malignancies, cardiovascular diseases such
as coronary heart disease and cardiomyopathy, diabetes
mellitus, cirrhosis and chronic renal failure requiring
haemodialysis), cardiac failure (according to the New York
Heart Association (NYHA) classification [11]), treatment and
outcome were recorded. Echocardiography data obtained by
trans-thoracic echocardiography and ⁄ or trans-oesophageal
echocardiography were also included. Microbiological data
provided by blood cultures, obtained according to the Duke
criteria, or by cultures from intra-operative cardiac tissue
samples, were recorded, as well as blood serology results for
miscellaneous microorganisms. Pathogens responsible for IE
were grouped as follows: streptococci (oral Streptococcus
spp., other non-enterococcal Streptococcus spp. and group D
streptococci, formerly Streptococcus bovis); Enterococcus
spp.; Staphylococcus aureus; coagulase-negative staphylococci
(CoNS); and ‘others’ (HACEK group (Haemophilus,
Actino-bacillus, Cardiobacterium, Eikenella, Kingella), fungi,
Gram-negative microorganisms, miscellaneous pathogens).
Culture-negative IE was defined as all cases of IE with
negative blood and ⁄or intra-operative cultures.
NIE was defined as IE associated with medical procedures
performed in hospital within the 8-week period before the
onset of the disease, and ⁄ or IE occurring ‡48 h after admission
[2,3]; all other cases were defined as CIE. The NIE and CIE
groups both included cases of NVE and PVE, with the latter
classified as ‘early’ or ‘late’ (occurring <2 months or
>2 months, respectively, after the initial valve replacement)
[2]. Cases of pacemaker endocarditis were excluded in order to
avoid referral bias, as relevant data were not provided
regularly by all the participating centres.
All case report forms were validated by the principal
investigators to ascertain that the Duke criteria for IE were
met. Incidence values were calculated according to the
population of Athens, obtained from the most recent census
conducted in Greece during 2001 by the National Statistical
Service.
Results are presented as median and inter-quartile ranges
or rates, as appropriate. Group differences for continuous and
categorical variables between cases of NIE and CIE were
evaluated by the Wilcoxon rank sum and Fisher’s exact tests,
respectively. Predictors of mortality were assessed using
logistic regression. Variables found to be significant in univa-
riate analysis (p <0.1), and variables with biological signifi-
cance (e.g., age), were included in a multivariate logistic
regression model, with p <0.05 considered to be significant. All
statistical tests were two-tailed. Statistical analyses were
performed using SPSS v.10 software (SPSS Inc., Chicago, IL,
USA).
RESULTS
In total, 223 cases of IE were registered within the
study period and region, but nine cases were
excluded by the Duke criteria, and 19 cases
classified as pacemaker endocarditis were also
excluded (full data not provided). Of the remain-
ing 195 eligible cases, 166 (85.1%) were classified
as definite and 29 (14.9%) as possible cases of IE
according to the Duke criteria. Possible IE was
defined by one major criterion and two minor
criteria (n = 21 ⁄ 29, 72.5%) and by one major and
one minor criterion (n = 8 ⁄ 29, 27.5%). NIE was
documented in 42 (21.5%) and CIE in 153 (78.5%)
of the 195 cases. The distribution of definite cases
of NIE and CIE, as well as of NVE and PVE, is
summarised in Fig. 1. The overall incidence of IE
in the Athens area was estimated at 2.1
cases ⁄ 100 000 inhabitant-years.
Demographical and clinical features of NIE and
CIE are summarised in Table 1. NIE and CIE both
affected mostly males and patients aged
‡60 years; NIE was also twice as frequent in this
age group (27% vs. 11.6%, p 0.017). Predisposing
factors for IE did not differ among cases of NIE
and CIE, except that injection drug use was





































Fig. 1. Distribution of 235 recorded
cases within the infective endocar-
ditis (IE) database, and classification
as definite or possible cases of infec-
tive endocarditis according to the
Duke criteria. PME, pacemaker
endocarditis; NIE, nosocomial infec-
tive endocarditis; CIE, community-
acquired infective endocarditis;
PVE, prosthetic valve endocarditis;
NVE, native valve endocarditis.
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associated exclusively with cases of CIE. Patients
with NIE presented significantly more often with
underlying diseases, e.g., diabetes mellitus, malig-
nancies, chronic renal failure requiring haemodi-
alysis and cardiovascular disease. PVE was more
frequent in the NIE group than in the CIE group
(33.3% vs. 18.3%, p <0.01). NIE was associated
with the following procedures: cardiothoracic
surgery (n = 11), arterio-venous fistulae (n = 2),
central (n = 8) ⁄peripheral (n = 3) intravascular
catheterisation, genitourinary tract procedures
(n = 3), abdominal (n = 8), orthopaedic (n = 2)
and head and neck (n = 1) surgery and heart
catheterisation (n = 4). Cardiac surgery included
coronary by-pass (n = 3), insertion of prosthetic
valve (n = 5), thoracic aortic graft (n = 1), pros-
thetic valve plus coronary by-pass (n = 1), and
Bentall-type surgery (n = 1). Trans-oesophageal
echocardiography was performed in 82.5% of
cases, and established the diagnosis of IE in 93.6%
and 86% cases of NVE and PVE, respectively.
Trans-thoracic echocardiography revealed cardiac
lesions compatible with IE in only 45% and 21%
of cases of NVE and PVE, respectively (p <0.001).
Microbiological documentation of IE was based
on the detection of positive blood cultures, as
either a major or a minor diagnostic criterion of IE
[10]. In three cases, diagnosis of IE was estab-
lished by both blood and intra-operative valve
cultures, while one case established the diagnosis
of Coxiella burnetii IE by PCR with material from
the cardiac valve, together with blood serology.
Overall, blood serology was diagnostic for only
four cases of culture-negative IE. Staphylococci
accounted for 53 (27.2%) of 195 cases. CoNS were
significantly more prominent in the NIE than in
the CIE group (26.2% vs. 5.2%, respectively,
p <0.001) (Table 1). Furthermore, 58% of cases
involving CoNS affected prosthetic valves.
S. aureus accounted for 11.9% of the cases of
NIE. No difference in the rates of S. aureus NIE
and CIE was observed. Methicillin resistance was
expressed by 29.5% of S. aureus isolates and
73.7% of CoNS isolates. No methicillin-resistant
S. aureus isolates were detected in the CIE group.
Overall, staphylococcal NIE (n = 16) was associ-
ated mainly with central ⁄peripheral intravascular
procedures (n = 8) and heart catheterisations
(n = 1), or abdominal (n = 2), orthopaedic (n = 1)
and cardiac (n = 4) surgery.
Non-enterococcal streptococci predominated
among patients with CIE (p <0.001). Enterococcus
spp. accounted for 38 (19.5%) of 195 IE cases, and
were significantly more prevalent in the NIE than
in the CIE group (30.9% vs. 16.3%, p 0.05)
(Table 1). Only one vancomycin-resistant Entero-
coccus spp. isolate was detected. Enterococcal NIE
(n = 13) was associated with a variety of medical
procedures, including abdominal surgery (n = 4),
genitourinary procedures (n = 3), heart catheter-
isation (n = 2), central intravascular catheterisa-
tion (n = 1), arterio-venous fistula infection
(n = 1) and coronary by-pass (n = 2). Empirical
antimicrobial treatment as an outpatient, before
diagnosis and hospitalisation for IE, occurred in
60% of the cases in the present series.
Left-sided IE accounted for almost 95% of
cases. The aortic valve was involved in NIE more
often than in CIE (61.9% vs. 37.2%, p <0.01),
while the mitral valve was more frequently
involved in CIE than in NIE (58.2% vs. 33.3%,
Table 1. Comparison of clinical characteristics of nosoco-
mial infective endocarditis (NIE) and community-acquired
infective endocarditis (CIE)
Variables NIE (n = 42) CIE (n = 153) p
Male, n (%) 32 (76.2) 94 (61.4) 0.1
Age (median ± IQR) 64.5 (61.5–70.5) 63 (52.5–72.5) 0.3
Predisposing IE factors, n (%)
History of valve diseasea 14 (33.3) 56 (36.6) 0.9
History of rheumatic fever 3 (7.2) 25 (16.3) 0.2
History of IE 4 (9.5) 15 (9.8) 1.0
Intravenous drug use 0 14 (9.2) 0.04
Co-morbidities, n (%)
Malignancies 9 (21.4) 9 (5.9) 0.005
CV diseaseb 23 (54.7) 50 (32.7) 0.01
Cirrhosis 2 (4.7) 9 (5.9) 1.0
Chronic renal failurec 5 (11.9) 2 (1.3) 0.006
Diabetes mellitus 13 (30.9) 26 (16.9) 0.05
Pathogens, n (%)
Streptococci (non-enterococci)d 3 (7.2) 54 (35.3) <0.001
Staphylococcus aureus 5 (11.9) 29 (18.9) 0.4
CoNSe 11 (26.2) 8 (5.2) <0.001
Enterococcus spp.f 13 (30.9) 25 (16.3) 0.05
Culture-negative IE 4 (9.5) 33 (21.5) 0.1
Affected valve, n (%)
Tricuspid 2 (4.7) 11 (7.2) 0.7
Aortic 26 (61.9) 57 (37.2) 0.007
Mitral 14 (33.3) 89 (58.2) 0.005
Prosthetic valve IE n (%) 14 (33.3) 28 (18.3) 0.06
Cardiac failure NYHA III–IV, n (%) 14 (33.3) 53 (34.6) 1.0
Embolic manifestationsg, n (%) 19 (45.2) 47 (30.7) 0.1
Surgical treatment, n (%) 7 (17.9)h 46 (31.1)h 0.1
In-hospital mortality, n (%) 15 (39.5)h 24 (18.6)h 0.02
IQR, inter-quartile range; IE, infective endocarditis; CV, cardiovascular; NYHA,
New York Heart Association.
aIncluding valve prolapse, regurgitation, stenosis, and bicuspid aortic valve.
bIncluding arterial hypertension, coronary heart disease, and cardiomyopathy.
cChronic renal failure requiring haemodialysis.
dViridans streptococci (n = 40), group D streptococci (n = 9), Streptococcus agalactiae
(n = 3), Streptococcus spp. (n = 4), Streptococcus pneumoniae (n = 1).
eCoagulase-negative staphylococci (CoNS), including Staphylococcus epidermidis
(n = 15), Staphylococcus haemolyticus (n = 2), CoNS not further identified (n = 2).
fEnterococcus spp. (n = 9), Enterococcus faecalis (n = 25), Enterococcus faecium (n = 1),
Enterococcus durans (n = 3).
gIncluding Janeway lesions, cerebral haemorrhage, and conjunctival haemorrhage.
hData missing in surgical treatment (NIE, n = 3; CIE, n = 5) and in-hospital
mortality (NIE, n = 4; CIE, n = 24).
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p <0.005). Similar rates of severe cardiac failure
(NYHA grades III–IV) were observed among both
NIE and CIE patients. Embolic manifestations, as
well as rates of surgery, were slightly increased in
the NIE group, although the difference did not
reach statistical significance. In-hospital mortality
was much higher for NIE than for CIE patients
(39.5% vs. 18.6%, p <0.05) (Table 1).
Table 2 summarises the results of univariate
analysis of potential predictors of mortality. NIE,
PVE, chronic renal failure requiring haemodialy-
sis, CoNS as the cause of IE and the presence of
cardiac failure (NYHA grades III–IV) were found
to have a significant impact on in-hospital mor-
tality (p £0.05). In a multivariate logistic regres-
sion model that adjusted for CoNS, a diagnosis of
NIE and chronic renal failure, the presence of
cardiac failure (NYHA grades III–IV) (OR 13.3,
95% CI 4.9–36.1, p <0.001) and a diagnosis of
PVE (OR 3.7, 95% CI 1.3–10.6, p 0.01) were im-
portant predictors of mortality.
Surgical treatment for IE did not seem to
influence mortality in the statistical models. In
order to further investigate whether surgery for IE
influenced survival, in-hospital mortality was
Table 2. Summary of univariate analysis of potential
predictors of mortality in patients with infective endocar-
ditis
Variables




p OR (95% CI)
Age (years)
20–39 0.7 0.7 (0.2–2.3)
Yes 5 ⁄ 18
No 34 ⁄ 149
40–59 0.4 1.6 (0.6–4)
Yes 7 ⁄ 41
No 32 ⁄ 126
60–80 0.7 0.8 (0.4–1.7)
Yes 24 ⁄ 98
No 15 ⁄ 69
>80 1.0 0.9 (0.2–3.5)
Yes 3 ⁄ 12
No 36 ⁄ 155
>60 0.7 1.2 (0.5–2.6)
Yes 12 ⁄ 57
No 27 ⁄ 110
Gender 0.9 1 (0.5–2.3)
Male 24 ⁄ 105
Female 15 ⁄ 62
NIE 0.02 2.9 (1.3–6.3)
Yes 15 ⁄ 38
No (CIE) 24 ⁄ 129
PVE 0.02 2.7 (1.2–6)
Yes 14 ⁄ 36
No (NVE) 25 ⁄ 131
IE predisposing factorsa
Valve disease 0.6 1.3 (0.6–2.7)
Yes 16 ⁄ 61
No 23 ⁄ 106
History of rheumatic fever 0.6 0.6 (0.2–1.9)
Yes 4 ⁄ 24
No 35 ⁄ 143
History of IE 0.8 1.2 (0.4–4.1)
Yes 4 ⁄ 15
No 35 ⁄ 152
Intravenous drug use 0.7 1.3 (0.3–5)
Yes 3 ⁄ 11
No 36 ⁄ 156
Co-morbidities
Malignancies 0.4 1.8 (0.6–5)
Yes 6 ⁄ 18
No 33 ⁄ 149
CV diseasesb 0.9 1 (0.5–2.3)
Yes 14 ⁄ 58
No 25 ⁄ 109
Cirrhosis 0.4 2.1 (0.5–9)
Yes 3 ⁄ 8
No 36 ⁄ 159
Chronic renal failurec 0.05 4.8 (1–22.3)
Yes 4 ⁄ 7
No 35 ⁄ 160
Diabetes mellitus 0.8 1.2 (0.5–2.8)
Yes 9 ⁄ 35
No 30 ⁄ 132
Table 2. (Continued)
Variables




p OR (95% CI)
Pathogens
Streptococci (non-enterococci)d 0.04 0.4 (0.2–0.9)
Yes 6 ⁄ 48
No 33 ⁄ 119
Staphylococcus aureus 0.8 1.1 (0.4–2.9)
Yes 7 ⁄ 28
No 32 ⁄ 129
CoNSe 0.002 6.1 (2–18.5)
Yes 9 ⁄ 15
No 30 ⁄ 152
Enterococcus spp.f 0.8 1 (0.5–2.5)
Yes 9 ⁄ 37
No 30 ⁄ 130
Culture-negative IE 0.6 0.7 (0.3–2)
Yes 6 ⁄ 31
No 33 ⁄ 136
Affected valve
Tricuspid 1.0 0.8 (0.2–4)
Yes 2 ⁄ 10
No 37 ⁄ 157
Aortich 1.0 0.9 (0.5–2)
Yes 16 ⁄ 70
No 22 ⁄ 92
Mitralh 1.0 1 (0.5–2.1)
Yes 21 ⁄ 90
No 17 ⁄ 73
Cardiac failure (NYHA grades III–IV) <0.001 7.1 (3.3–15.7)
Yes 26 ⁄ 54
No 13 ⁄ 113
Embolic manifestationsg 0.2 1.8 (0.8–3.7)
Yes 17 ⁄ 56
No 22 ⁄ 111
Surgical treatmenth 0.7 0.8 (0.3–1.9)
Yes 8 ⁄ 39
No 31 ⁄ 127
NIE, nosocomial infective endocarditis; CIE, community-acquired infective endo-
carditis; PVE, prosthetic valve endocarditis; NVE, native valve endocarditis; IE,
infective endocarditis; CV, cardiovascular; CoNS, coagulase-negative staphylococci.
aIncluding valve prolapse, regurgitation, stenosis, and bicuspid aortic valve.
bIncluding arterial hypertension, coronary heart disease, and cardiomyopathy.
cChronic renal failure requiring haemodialysis.
dViridans group streptococci (n = 34), group D streptococci (n = 7), Streptococcus
agalactiae (n = 3), Streptococcus spp. (n = 3), Streptococcus pneumoniae (n = 1).
eCoNS, including Staphylococcus epidermidis (n = 12), Staphylococcus haemolyticus
(n = 1), CoNS not further identified (n = 2).
fEnterococcus spp. (n = 8), Enterococcus faecalis (n = 25), Enterococcus faecium (n = 1),
Enterococcus durans (n = 3).
gIncluding Janeway lesions, cerebral haemorrhage, conjunctival haemorrhage.
hMissing data on mortality for aortic (n = 5) and mitral (n = 4) valves and surgical
treatment (n = 1).
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calculated for four subgroups of patients
with ⁄without cardiac failure and surgery for IE
(Table 3). There was a >three-fold increase in
mortality rate for patients with cardiac failure
(NYHA grades III–IV) who did not receive sur-
gery for IE, compared to patients with cardiac
failure who received surgery (85.7% vs. 25%,
p <0.001). Mortality was similar for patients who
received surgery for cardiac failure or other
reasons. No significant difference in mortality
was detected between patients with surgery for
cardiac failure and patients without cardiac failure
who received conservative treatment (Table 3).
DISCUSSION
This prospective cohort study demonstrated a
high incidence of NIE and the emergence of
enterococci as an important cause of endocarditis
in Greece. The changing profile of IE requires
continuous epidemiological updating [1,4]. Inva-
sive therapeutic interventions have increased in
the hospital environment during recent decades.
These procedures, particularly intravascular cath-
eterisations and the use of pacemaker devices and
dialysis shunts, have increased the risk of
nosocomial bacteraemia and subsequent NIE
[12]. In the present study, previous observations
concerning the emergence of NIE were confirmed
[13]. The overall population incidence of IE was
within the expected range [1], but NIE in the
present cohort exceeded the rates of 9–20%
reported previously [14]. In the present series,
elderly patients with severe co-morbidities who
underwent medical procedures or haemodialysis
were at risk for NIE, as reported previously [14].
Although patients with NIE were older [15], age
was not an independent predictor of mortality in
the present series. The higher incidence of NIE in
the elderly may be explained by the increased
frequency of hospitalisation and invasive medical
procedures in this age group. Patients with end-
stage renal failure are at high risk of developing
NIE resulting from nosocomial bacteraemia, with
S. aureus, followed by enterococci, being the
leading cause in such patients [16], and mortality
rates exceeding 50% in cases of NIE related to
haemodialysis [16].
To the best of our knowledge, the present study
is the first large cohort study of IE to identify
enterococci as a leading cause of NIE. Enterococ-
cal IE was related directly to in-hospital medical
procedures in 30.9% of cases, compared to only
15% of cases identified by the merged cohort of
the International Collaboration on Endocarditis
study [17]. Although 60% of cases of enterococcal
bacteraemia following common abdominal and
genitourinary procedures are nosocomial, 8–15%
of cases are complicated by IE [18,19]. However,
in the present series, six (46.2%) of 13 cases of
enterococcal NIE were attributed to intravascular
and heart catheterisations, as well as cardiac
surgery. Thus, the current analysis indicates that
other routes of enterococcal transmission are
probable. The high rates of enterococcal NIE
might be explained, in part, by the administration
of second-generation cephalosporins as standard
practice in surgical prophylaxis, but the relevant
data were not available for the current study. The
mortality associated with enterococcal IE was not
significantly higher in the present series, which
confirms the findings from previous studies
[17,18].
The updated epidemiological profile of IE
revealed significant changes compared with
results from a previous analysis of case series in
Greece [20]. In the previous series, conducted in a
single tertiary hospital and cardiosurgical unit
between 1996 and 2000, 101 cases of IE were
evaluated, revealing S. aureus to be the leading
cause of IE, with enterococci associated with only
6% of cases. Although these results derived from
a single institution and cannot be directly
compared with the present survey, trends of IE
in the Greek population seem to have changed
since 2000.
In the current analysis, streptococcal (non-
enterococcal) IE was mostly community-acquired,
as demonstrated previously [3,17]. S. aureus
bacteraemia can often result in IE, especially in
patients with prosthetic valves or underlying
Table 3. Mortality in four subgroups of patients















A Yes Yes 8 ⁄ 32 (25)
B Yes No 18 ⁄ 21 (85.7) A vs. B <0.0001
C No No 13 ⁄ 106 (12.3) A vs. C 0.09
D No Yes 0 ⁄ 7 A vs. D 0.3
aNo. of patients who died ⁄no. of patients in the subgroup (%); total no. of
deaths = 39; total no. of survivors = 127 (missing data, n = 1).
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valve damage. Although most series have
reported that S. aureus is the leading causative
agent of NIE and PVE, with a varying incidence
rate of 37–57% [13,21,22], this was not confirmed
by the present cohort analysis. Local variations
may be detected in different national surveys, but
according to analyses of merged databases world-
wide, S. aureus CIE seems to be more frequent in
Europe, while S. aureus NIE is detected more
often in the USA, where it has an important
impact on IE mortality [21]. However, recent
European case series have revealed that S. aureus
is increasingly important as a cause of NIE, cases
of which, in turn, are gradually increasing [23,24].
Moreover, methicillin-resistant S. aureus bacterae-
mia has been associated with NIE, especially in
the presence of co-morbidities [25]. In the present
series, S. aureus was neither a leading cause of
NIE nor a predictor of mortality.
It was interesting that CoNS showed an associ-
ation with mortality in the current analysis. CoNS
are well-known to be associated with catheter-
related nosocomial bacteraemia, which is an
important risk-factor for NIE [3,26]. In addition,
mortality associated with CoNS was important in
a recent analysis of 99 cases of NVE [26], and was
also shown to be high in patients with CoNS and
PVE, who were more likely to have chronic
diseases and healthcare-associated infections
[27]. Thus, the high mortality associated with
CoNS in the present study might be explained, in
part, by the strong association of CoNS with NIE
and prosthetic valves.
The proportion of culture-negative IE in the
CIE group could be attributed to the administra-
tion of empirical outpatient antimicrobial treat-
ment; 60% of the patients with symptoms of IE
(mostly fever) had received antimicrobial agents
before hospitalisation for IE, and before any blood
culture for IE was performed.
Cardiac failure and the presence of a prosthetic
valve were associated independently with early
mortality in the present multivariate model, and
NIE approached significance. These findings are
in agreement with previous reports [22]. Mortality
is generally accepted to be higher in cases of NIE
than in cases of CIE, probably because of
advanced age, frequent co-morbidities, the pres-
ence of a prosthetic valve, and the incidence of
staphylococcal bacteraemia [3,14,22]. Mortality
did not differ significantly among patients who
received surgery because of clear indications
(e.g., cardiac failure) and patients with no clear
indication for surgery who received only conser-
vative treatment. The mortality associated with IE
was higher in patients with cardiac failure who
did not undergo cardiosurgical intervention, as
also revealed by previous studies [2,21,22]. Car-
diosurgical intervention in the case of cardiac
failure is mandatory for patients with IE and must
not be delayed. The lower mortality observed in
surgically treated patients may be related to a
selection bias, since patients who died had indi-
cations for surgery, but did not receive surgery
because of other medical contraindications or for
administrative reasons.
The main strength of the present study is that
the population sample was collected prospec-
tively from 20 hospitals covering the major
metropolitan area of Athens, which contains
almost 40% of the Greek population. The sample
size was adequate to reach conclusions concern-
ing the disease. One significant limitation of the
study was the exclusion of pacemaker endocar-
ditis, which is associated mostly with NIE and is
an important parameter of nosocomial infections
[28]. In addition, although the pathogenesis of IE
attributed to cardiac surgery is different from that
of IE related to nosocomial bacteraemia [13], these
cases of NIE were also included in the present
cohort study in order to better assess hospital-
acquired IE in Greece. The impact of previous
administration of antimicrobial agents for surgical
prophylaxis on the incidence of enterococcal
bacteraemia and subsequent NIE needs to be
further investigated. Finally, it was not possible to
account for any residual confounding in the
associations identified.
In conclusion, the present analysis confirmed
that IE in a large proportion of the Greek popu-
lation follows the epidemiological features and
predictors for adverse outcome described in other
countries. The mortality of IE was high, especially
in patients with PVE, severe cardiac failure and
underlying end-stage renal disease. Enterococci
and methicillin-resistant CoNS appear to have
emerged as important causative agents of NIE,
indicating the need for a thorough investigation of
the potential risk-factors for enterococcal and
staphylococcal infection inGreekhospitals in order
to improve infection control policies. Clearly, there
is a need for continuous epidemiological surveil-
lance of IE, as the characteristics of the disease
appear to be evolving.
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SUPPLEMENTARY MATERIAL
The following supplementary material for this
article is available online at http://www.black
well-synergy.com:
Table S1 Members of the Hellenic Endocarditis
Study Group.
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